Noticias y Actividades de Kintor Pharmaceutical
Presencia
Kintor Pharmaceutical es una empresa que cotiza bajo el símbolo de cotización 9939 (CN).
Ejecutivos
Ver el organigrama con sus 15 ejecutivos principales
Biografías más buscadas en Kintor Pharmaceutical
- Youzhi Tong, Chief Executive Officer and Chairman of the Board
- Gao Weipeng, Non-Executive Director
- Wei Geqi, Non-Executive Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Kintor Pharmaceutical.
Farmacia
Kintor Pharmaceutical tiene 1.826 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Roche (Suiza).
Popular M&A news in Farmacia
- Cyclo Therapeutics ha Rafael Holdings adquirido (publicado el 28 de abril de 2025).
- Chimerix and Chimerix have merged (publicado el 22 de abril de 2025)..
- Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Kintor Pharmaceutical
- Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US_Kintor Pharmaceutical Limited
- Kintor Pharma Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematologic Malignancies in China_Kintor Pharmaceutical Limited
- Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China_Kintor Pharmaceutical Limited
- Kintor Pharma Announces 2022 Annual Results and Recent Business Progress _Kintor Pharmaceutical Limited
- Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China_Kintor Pharmaceutical Limited
- Kintor Pharma’s KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 _Kintor Pharmaceutical Limited
- Kintor Pharma Announces Preclinical Data of GT1708F at AACR 2023_Kintor Pharmaceutical Limited
- Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound_Kintor Pharmaceutical Limited
- Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met_Kintor Pharmaceutical Limited
- Kintor Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use_Kintor Pharmaceutical Limited
- View more press releases Close
Redes sociales sobre Kintor Pharmaceutical
- Kintor Pharmaceutical en Wikipedia, Google News y Yahoo Finance
- Kintor Pharmaceutical en LinkedIn, Twitter y YouTube
